QNP: Gastrointesinal Lesion Software Detection System
What it covers
A gastrointestinal lesion software detection system is a computer-assisted detection device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract. This device with advanced software algorithms brings attention to images to aid in the detection of lesions. The device may contain hardware to support interfacing with an endoscope.
FDA’s definition of product code QNP, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K260133 | CADDIE | Odin Medical Limited | Sep 12, 2026 | Special |
| K260567 | EW10-EC02 Endoscopy Support Program | Fujifilm Corporation | Aug 7, 2026 | Special |
| K252853 | CAD - Lower GI (EC07-01) | Xiamen Inno Medical Technology Co., Ltd. | Aug 5, 2026 | Traditional |
| K261369 | GI Genius Module 300 (GGM300-US);ColonPRO US (CPRO403S-US) | Cosmo Artificial Intelligence - Ai, Ltd. | May 29, 2026 | Special |
| K260724 | MAGENTIQ-COLO (ME-APDS) | Magentiq Eye, Ltd. | Apr 3, 2026 | Special |
| K253664 | SKOUT system | Iterative Health | Dec 22, 2025 | Special |
| K252178 | MAGENTIQ-COLO (ME-APDS) | Magentiq Eye, Ltd. | Oct 3, 2025 | Special |
| K252586 | CADDIE | Odin Medical Limited | Sep 12, 2025 | Special |
| K251126 | SKOUT system | Iterative Health | May 9, 2025 | Special |
| K244023 | MAGENTIQ-COLO (ME-APDS) | Magentiq Eye, Ltd. | Jan 24, 2025 | Special |
Clearances by year
23 QNP 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 5 | 169 |
| 2025 | 5 | 28 |
| 2024 | 5 | 29 |
| 2023 | 4 | 140 |
| 2022 | 1 | 263 |
| 2021 | 3 | 203 |
Who submits
8 applicants cleared a QNP device since 2011. 26% of the clearances went to applicants in Ireland, then United States (26%), Israel (17%) and United Kingdom (13%). By type: Special 70%, Traditional 26% and Direct 4%.
| Applicant | Clearances since 2011 |
|---|---|
| Cosmo Artificial Intelligence - Ai, Ltd. | 6 |
| Iterative Scopes, Inc. | 4 |
| Magentiq Eye, Ltd. | 4 |
| Odin Medical Limited | 3 |
| Fujifilm Corporation | 2 |
| Iterative Health | 2 |
| Chengdu Wision Medical Device Co., Ltd. | 1 |
| Xiamen Inno Medical Technology Co., Ltd. | 1 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including detection of gastrointestinal lesions and evaluation of all adverse events.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Testing must include:
(i) Standalone algorithm performance testing;
(ii) Pixel-level comparison of degradation of image quality due to the device;
(iii) Assessment of video delay due to marker annotation; and
(iv) Assessment of real-time endoscopic video delay due to the device.
(3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device.
(4) Performance data must demonstrate electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety testing for any hardware components of the device.
(5) Software verification, validation, and hazard analysis must be provided. Software description must include a detailed, technical description including the impact of any software and hardware on the device's functions, the associated capabilities and limitations of each part, the associated inputs and outputs, mapping of the software architecture, and a description of the video signal pipeline.
(6) Labeling must include:
(i) Instructions for use, including a detailed description of the device and compatibility information;
(ii) Warnings to avoid overreliance on the device, that the device is not intended to be used for diagnosis or characterization of lesions, and that the device does not replace clinical decision making;
(iii) A summary of the clinical performance testing conducted with the device, including detailed definitions of the study endpoints and statistical confidence intervals; and
(iv) A summary of the standalone performance testing and associated statistical analysis.
From 21 CFR 876.1520. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 876.1520 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QNP clearances declared.
Ask about QNP
Questions about QNP
What is FDA product code QNP?
Product code QNP, “Gastrointesinal Lesion Software Detection System” in FDA's classification database, is a Class II device type under 21 CFR 876.1520 (gastrointestinal lesion software detection system), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 23 clearances under QNP, 23 of them since 2011.
How many 510(k) clearances are there under QNP?
FDA’s 510(k) database listed 23 clearances under QNP as of Oct 29, 2026, 23 of them decided since 2011; the most recent decision was Sep 12, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a QNP 510(k)?
For the 10 QNP clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 32 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most QNP clearances?
Since 2011: Cosmo Artificial Intelligence - Ai, Ltd. (6), Iterative Scopes, Inc. (4), Magentiq Eye, Ltd. (4), Odin Medical Limited (3) and Fujifilm Corporation (2). 8 applicants have cleared a QNP device in that time.